Led by Prof. Dr. Marianne Brodmann, PI of clinical studies for the Lumee™ Oxygen CE Mark, collaboration includes practice adoption and platform integration in cases and clinical study programs BERKELEY, Calif, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual’s biochemistry, announces a commercial and clinical collabora ...

BERKELEY, Calif, July 31, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (NASDAQ: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual’s biochemistry, announces it has signed a Letter of Intent (LOI) to enter into a distribution agreement in Spain for its Lumee Oxygen platform. The Spanish distributor, Dismeval, S.L., specializes in the distribution of medical and surgical equipment thr ...